- Home
- GH
as 05-30-2025 10:36am EST
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 5.5B | IPO Year: | 2018 |
| Target Price: | $52.81 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.14 - $52.92 | Next Earning Date: | 04-30-2025 |
| Revenue: | $773,996,000 | Revenue Growth: | 28.20% |
| Revenue Growth (this year): | 23.05% | Revenue Growth (next year): | 21.40% |
Stock Insider Trading Activity of Guardant Health Inc. (GH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tariq Musa | GH | Director | May 19 '25 | Sell | $40.04 | 116 | $4,644.64 | 3,479 | |
| Talasaz AmirAli | GH | Co-Chief Executive Officer | May 1 '25 | Sell | $50.20 | 120,716 | $5,936,572.01 | 2,252,910 | |
| Tariq Musa | GH | Director | Apr 17 '25 | Sell | $44.79 | 116 | $5,195.64 | 3,479 | |
| Tariq Musa | GH | Director | Mar 19 '25 | Sell | $43.70 | 116 | $5,069.20 | 3,479 | |
| Kalia Kumud | GH | Chief Information Officer | Mar 15 '25 | Sell | $43.16 | 3,500 | $151,060.35 | 19,720 | |
| Joyce Meghan V. | GH | Director | Mar 3 '25 | Sell | $42.71 | 100 | $4,271.00 | 7,647 |
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
StockStory
2 days ago
Firing on All Cylinders: Guardant Health (NASDAQ:GH) Q1 Earnings Lead the Way
Business Wire
3 days ago
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
The Wall Street Journal
7 days ago
New Tests Promise to Reveal the Secrets in Your Blood
Business Wire
8 days ago
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
StockStory
9 days ago
Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know
Insider Monkey
9 days ago
Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio
MT Newswires
9 days ago
Guardant Health Launches Immunohistochemistry Testing for Solid Tumors
Business Wire
9 days ago
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors
Compare GH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.